269 related articles for article (PubMed ID: 30427714)
21. Safety evaluation of combination doxorubicin and toceranib phosphate (Palladia®) in tumour bearing dogs: a phase I dose-finding study.
Pellin MA; Wouda RM; Robinson K; Tsimbas K; Kurzman ID; Biller BJ; Vail DM
Vet Comp Oncol; 2017 Sep; 15(3):919-931. PubMed ID: 27146577
[TBL] [Abstract][Full Text] [Related]
22. Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): a phase I dose-finding study.
Chon E; McCartan L; Kubicek LN; Vail DM
Vet Comp Oncol; 2012 Sep; 10(3):184-93. PubMed ID: 22235941
[TBL] [Abstract][Full Text] [Related]
23. Treatment of insulinoma in a springer spaniel with streptozotocin.
Bell R; Mooney CT; Mansfield CS; Jones BR
J Small Anim Pract; 2005 May; 46(5):247-50. PubMed ID: 15909449
[TBL] [Abstract][Full Text] [Related]
24. Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia(®) ) in tumour-bearing dogs: a phase I dose-finding study.
Pan X; Tsimbas K; Kurzman ID; Vail DM
Vet Comp Oncol; 2016 Jun; 14(2):202-9. PubMed ID: 24735385
[TBL] [Abstract][Full Text] [Related]
25. A canine case of malignant melanoma carrying a KIT c.1725_1733del mutation treated with toceranib: a case report and in vitro analysis.
Tani H; Miyamoto R; Noguchi S; Kurita S; Nagashima T; Michishita M; Yayoshi N; Tamura K; Bonkobara M
BMC Vet Res; 2021 Apr; 17(1):147. PubMed ID: 33827546
[TBL] [Abstract][Full Text] [Related]
26. Toceranib phosphate-associated nephrotic syndrome in a dog: a case report.
Remerowski SM; Herrera CL; Donnelly LL
BMC Vet Res; 2021 Apr; 17(1):146. PubMed ID: 33827545
[TBL] [Abstract][Full Text] [Related]
27. Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs.
Berger EP; Johannes CM; Jergens AE; Allenspach K; Powers BE; Du Y; Mochel JP; Fox LE; Musser ML
J Vet Intern Med; 2018 Nov; 32(6):2045-2053. PubMed ID: 30307656
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the long-acting somatostatin analogue octreotide in the management of insulinoma in three dogs.
Simpson KW; Stepien RL; Elwood CM; Boswood A; Vaillant CR
J Small Anim Pract; 1995 Apr; 36(4):161-5. PubMed ID: 7603057
[TBL] [Abstract][Full Text] [Related]
29. The impact of toceranib, piroxicam and thalidomide with or without hypofractionated radiation therapy on clinical outcome in dogs with inflammatory mammary carcinoma.
Rossi F; Sabattini S; Vascellari M; Marconato L
Vet Comp Oncol; 2018 Dec; 16(4):497-504. PubMed ID: 29806156
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.
Bernabe LF; Portela R; Nguyen S; Kisseberth WC; Pennell M; Yancey MF; London CA
BMC Vet Res; 2013 Sep; 9():190. PubMed ID: 24079884
[TBL] [Abstract][Full Text] [Related]
31. c-Kit Mutation and Localization Status as Response Predictors in Mast Cell Tumors in Dogs Treated with Prednisone and Toceranib or Vinblastine.
Weishaar KM; Ehrhart EJ; Avery AC; Charles JB; Elmslie RE; Vail DM; London CA; Clifford CA; Eickhoff JC; Thamm DH
J Vet Intern Med; 2018 Jan; 32(1):394-405. PubMed ID: 29194765
[TBL] [Abstract][Full Text] [Related]
32. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
London CA; Malpas PB; Wood-Follis SL; Boucher JF; Rusk AW; Rosenberg MP; Henry CJ; Mitchener KL; Klein MK; Hintermeister JG; Bergman PJ; Couto GC; Mauldin GN; Michels GM
Clin Cancer Res; 2009 Jun; 15(11):3856-65. PubMed ID: 19470739
[TBL] [Abstract][Full Text] [Related]
33. Retrospective evaluation of toceranib phosphate (Palladia) in the treatment of canine carcinomatosis and mesothelioma.
Hicks KA; Leeper HJ; Curran KM
Vet Comp Oncol; 2024 Jun; 22(2):245-254. PubMed ID: 38622074
[TBL] [Abstract][Full Text] [Related]
34. Retrospective evaluation of toceranib (Palladia) treatment for canine metastatic appendicular osteosarcoma.
Kim C; Matsuyama A; Mutsaers AJ; Woods JP
Can Vet J; 2017 Oct; 58(10):1059-1064. PubMed ID: 28966355
[TBL] [Abstract][Full Text] [Related]
35. Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study.
Wouda RM; Hocker SE; Higginbotham ML
Vet Comp Oncol; 2018 Mar; 16(1):E52-E60. PubMed ID: 28799187
[TBL] [Abstract][Full Text] [Related]
36. Use of Toceranib Phosphate in the Treatment of Canine Bladder Tumors: 37 Cases.
Gustafson TL; Biller B
J Am Anim Hosp Assoc; 2019; 55(5):243-248. PubMed ID: 31433219
[No Abstract] [Full Text] [Related]
37. The impact of carboplatin and toceranib phosphate on serum vascular endothelial growth factor (VEGF) and metalloproteinase-9 (MMP-9) levels and survival in canine osteosarcoma.
Gieger TL; Nettifee-Osborne J; Hallman B; Johannes C; Clarke D; Nolan MW; Williams LE
Can J Vet Res; 2017 Jul; 81(3):199-205. PubMed ID: 28725110
[TBL] [Abstract][Full Text] [Related]
38. Long-term clinical control of feline pancreatic carcinoma with toceranib phosphate.
Dedeaux AM; Langohr IM; Boudreaux BB
Can Vet J; 2018 Jul; 59(7):751-754. PubMed ID: 30026621
[TBL] [Abstract][Full Text] [Related]
39. Combination toceranib and lomustine shows frequent high grade toxicities when used for treatment of non-resectable or recurrent mast cell tumours in dogs: A European multicentre study.
Bavcar S; de Vos J; Kessler M; de Fornel P; Buracco P; Murphy S; Hirschberger J; Argyle DJ
Vet J; 2017 Jun; 224():1-6. PubMed ID: 28697868
[TBL] [Abstract][Full Text] [Related]
40. Insulinoma in the ferret: clinical findings and treatment comparison of 66 cases.
Weiss CA; Williams BH; Scott MV
J Am Anim Hosp Assoc; 1998; 34(6):471-5. PubMed ID: 9826281
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
